CSIMarket
 


Coherus Biosciences inc   (CHRS)
Other Ticker:  
 


Coherus Biosciences Inc 's Net Cash Flow Margin by quarter

Trends, Rankings, Statistics



CHRS Net Cash Flow Margin (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Revenue Change 101.81 % 64.16 % -2.39 % -46.04 % -38.19 %
Seq. Revenue Change 22.74 % 27 % 81.02 % -28.48 % -0.16 %
Revenue In Millions $91.52 $74.57 $58.72 $32.44 $45.35
Net Cash Flow Margin 24.73 % 9.86 % 96.69 % -146.14 % -492.28 %
Net Cash Flow Margin Total Ranking # 499 # 1088 # 338 # # 1
Net Cash Flow In Millions $22.63 $7.35 $56.78 $-47.40 $-223.26
Y / Y Net Cash Flow Change - -35.07 % - - -
Seq. Net Cash Flow Change 207.88 % -87.05 % - - -


Commenting fourth Quarter 2023 Net Cash Flow Margin
Company's Net Cash Flow Margin improved in IV. Quarter to 24.73 %, below company's average Net Cash Flow Margin.

Observing fourth quarter 2023 results within Biotechnology & Pharmaceuticals industry 18 other companies have achieved higher Net Cash Flow Margin. While Net Cash Flow Margin total ranking has impoved so far to 499, from total ranking in previous quarter at 1088.

CHRS's Net Cash Flow Margin fourth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 19
Healthcare Sector # 100
Overall # 499

Net Cash Flow Margin Statistics
High Average Low
1324.67 % 172.12 % 9.86 %
(Jun 30 2015)   (Sep 30 2023)




Other Net Cash Flow Margin Profitability Ratios
CHRS's Cumulative Net Cash Flow Margin
Biotechnology & Pharmaceuticals Industry Net Cash Flow Margin Trends and Statistics
Healthcare Sector Net Cash Flow Margin Statistics
Net Cash Flow Margin Profitability Trends for overall market
CHRS's Net Cash Flow Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Margin
Lowest Ranking Net Cash Flow Margin
Net Cash Flow Margin Profit Margin for CHRS's Competitors
Net Cash Flow Margin Profit Margin for Coherus Biosciences Inc 's Suppliers
Net Cash Flow Margin Profit Margin for CHRS's Customers

You may also want to know
CHRS's Annual Growth Rates CHRS's Profitability Ratios CHRS's Asset Turnover Ratio CHRS's Dividend Growth
CHRS's Roe CHRS's Valuation Ratios CHRS's Financial Strength Ratios CHRS's Net Cash Flow Growth
CHRS's Roa CHRS's Inventory Turnover Ratio CHRS's Growth Rates CHRS's Dividend Comparisons


Companies with similar Net Cash Flow Margin in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Net Cash Flow MarginDec 31 2023 MRQ Net Cash FlowDec 31 2023 MRQ Revenue
Vaxart Inc   46.75 %$ 1.517 $ 3.245 
Recursion Pharmaceuticals Inc   38.73 %$ 4.218 $ 10.891 
Argenx se  32.09 %$ 800.740 $ 2,494.910 
Protalix Biotherapeutics inc   30.76 %$ 3.226 $ 10.486 
Coherus Biosciences inc   24.73 %$ 22.632 $ 91.524 
Gilead Sciences Inc   5.34 %$ 380.000 $ 7,114.000 
Vericel Corporation  5.08 %$ 3.305 $ 64.996 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com